Emergent BioSolutions Inc. will help produce COVID-19 vaccines in Baltimore and Rockville under a federal contract.
Gaithersburg-based Emergent said Tuesday it will manufacture vaccines under an existing contract with a division of U.S. Department of Health & Human Services, assisting government efforts to fast-track the vaccine. Emergent has long worked with the federal health agency’s Biomedical Advanced Research and Development Authority.
“Our longstanding record of delivering safe and effective medical countermeasures for public health positions us to continue to help at this critical moment," said Robert G. Kramer, Emergent’s president and CEO.
Emergent will create a U.S.-based system to make vaccines that are being developed by pharmaceutical and biotechnology companies.
The new $628 million job will be done under a 2012 contract with Biomedical Advanced Research that had established Emergent’s Baltimore Bayview facility as an innovation center for pandemic preparedness. The center can rapidly make large quantities of vaccines and treatments during public health emergencies
New investments in Emergent’s Camden and Rockville facilities will allow those locations and Bayview to produce COVID-19 vaccine candidates through next year. The Bayview facility has capacity to produce tens to hundreds of millions of doses of vaccine on an annual basis.
Separately from the federal contract, Emergent is collaborating on COVID-19 vaccines with with Johnson & Johnson, Novavax, and Vaxart.